Hospitalization and Mortality due to Infection among United States Children and Adolescents with Systemic Lupus Erythematosus
CONCLUSION: Hospitalizations with codes for for infection comprised a small proportion of cSLE admissions but accounted for the majority of mortality. The proportion of hospitalizations for infection increased over time. Lupus nephritis and ESRD were risk factors for poor outcomes.PMID:38561187 | DOI:10.3899/jrheum.2023-1219 (Source: J Rheumatol)
Source: J Rheumatol - April 1, 2024 Category: Rheumatology Authors: Jordan E Roberts Anna Faino Mersine A Bryan Jonathan D Cogen Esi M Morgan Source Type: research
Lupus Nephritis Treatment Strategies
J Rheumatol. 2024 Apr 1:jrheum.2024-0172. doi: 10.3899/jrheum.2024-0172. Online ahead of print.ABSTRACTLupus nephritis (LN) is present in approximately 25% to 50% of patients at the time of systemic lupus erythematosus diagnosis and eventually develops in up to 60% of adults and 80% of children.1 Over the past 5 decades, major advances in immunosuppressive medications for patients with severe LN (classes III, IV, and V alone or in combination) have resulted in significant improvements in patient survival.2.PMID:38561191 | DOI:10.3899/jrheum.2024-0172 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - April 1, 2024 Category: Rheumatology Authors: Gabriel Nicolas Contreras Martin Source Type: research
Hospitalization and Mortality due to Infection among United States Children and Adolescents with Systemic Lupus Erythematosus
CONCLUSION: Hospitalizations with codes for for infection comprised a small proportion of cSLE admissions but accounted for the majority of mortality. The proportion of hospitalizations for infection increased over time. Lupus nephritis and ESRD were risk factors for poor outcomes.PMID:38561187 | DOI:10.3899/jrheum.2023-1219 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - April 1, 2024 Category: Rheumatology Authors: Jordan E Roberts Anna Faino Mersine A Bryan Jonathan D Cogen Esi M Morgan Source Type: research
Lupus Nephritis Treatment Strategies
J Rheumatol. 2024 Apr 1:jrheum.2024-0172. doi: 10.3899/jrheum.2024-0172. Online ahead of print.ABSTRACTLupus nephritis (LN) is present in approximately 25% to 50% of patients at the time of systemic lupus erythematosus diagnosis and eventually develops in up to 60% of adults and 80% of children.1 Over the past 5 decades, major advances in immunosuppressive medications for patients with severe LN (classes III, IV, and V alone or in combination) have resulted in significant improvements in patient survival.2.PMID:38561191 | DOI:10.3899/jrheum.2024-0172 (Source: J Rheumatol)
Source: J Rheumatol - April 1, 2024 Category: Rheumatology Authors: Gabriel Nicolas Contreras Martin Source Type: research
Hospitalization and Mortality due to Infection among United States Children and Adolescents with Systemic Lupus Erythematosus
CONCLUSION: Hospitalizations with codes for for infection comprised a small proportion of cSLE admissions but accounted for the majority of mortality. The proportion of hospitalizations for infection increased over time. Lupus nephritis and ESRD were risk factors for poor outcomes.PMID:38561187 | DOI:10.3899/jrheum.2023-1219 (Source: J Rheumatol)
Source: J Rheumatol - April 1, 2024 Category: Rheumatology Authors: Jordan E Roberts Anna Faino Mersine A Bryan Jonathan D Cogen Esi M Morgan Source Type: research
Lupus Nephritis Treatment Strategies
J Rheumatol. 2024 Apr 1:jrheum.2024-0172. doi: 10.3899/jrheum.2024-0172. Online ahead of print.ABSTRACTLupus nephritis (LN) is present in approximately 25% to 50% of patients at the time of systemic lupus erythematosus diagnosis and eventually develops in up to 60% of adults and 80% of children.1 Over the past 5 decades, major advances in immunosuppressive medications for patients with severe LN (classes III, IV, and V alone or in combination) have resulted in significant improvements in patient survival.2.PMID:38561191 | DOI:10.3899/jrheum.2024-0172 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - April 1, 2024 Category: Rheumatology Authors: Gabriel Nicolas Contreras Martin Source Type: research
Hospitalization and Mortality due to Infection among United States Children and Adolescents with Systemic Lupus Erythematosus
CONCLUSION: Hospitalizations with codes for for infection comprised a small proportion of cSLE admissions but accounted for the majority of mortality. The proportion of hospitalizations for infection increased over time. Lupus nephritis and ESRD were risk factors for poor outcomes.PMID:38561187 | DOI:10.3899/jrheum.2023-1219 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - April 1, 2024 Category: Rheumatology Authors: Jordan E Roberts Anna Faino Mersine A Bryan Jonathan D Cogen Esi M Morgan Source Type: research
Lupus Nephritis Treatment Strategies
J Rheumatol. 2024 Apr 1:jrheum.2024-0172. doi: 10.3899/jrheum.2024-0172. Online ahead of print.ABSTRACTLupus nephritis (LN) is present in approximately 25% to 50% of patients at the time of systemic lupus erythematosus diagnosis and eventually develops in up to 60% of adults and 80% of children.1 Over the past 5 decades, major advances in immunosuppressive medications for patients with severe LN (classes III, IV, and V alone or in combination) have resulted in significant improvements in patient survival.2.PMID:38561191 | DOI:10.3899/jrheum.2024-0172 (Source: J Rheumatol)
Source: J Rheumatol - April 1, 2024 Category: Rheumatology Authors: Gabriel Nicolas Contreras Martin Source Type: research
Hospitalization and Mortality due to Infection among United States Children and Adolescents with Systemic Lupus Erythematosus
CONCLUSION: Hospitalizations with codes for for infection comprised a small proportion of cSLE admissions but accounted for the majority of mortality. The proportion of hospitalizations for infection increased over time. Lupus nephritis and ESRD were risk factors for poor outcomes.PMID:38561187 | DOI:10.3899/jrheum.2023-1219 (Source: J Rheumatol)
Source: J Rheumatol - April 1, 2024 Category: Rheumatology Authors: Jordan E Roberts Anna Faino Mersine A Bryan Jonathan D Cogen Esi M Morgan Source Type: research
Lupus Nephritis Treatment Strategies
J Rheumatol. 2024 Apr 1:jrheum.2024-0172. doi: 10.3899/jrheum.2024-0172. Online ahead of print.ABSTRACTLupus nephritis (LN) is present in approximately 25% to 50% of patients at the time of systemic lupus erythematosus diagnosis and eventually develops in up to 60% of adults and 80% of children.1 Over the past 5 decades, major advances in immunosuppressive medications for patients with severe LN (classes III, IV, and V alone or in combination) have resulted in significant improvements in patient survival.2.PMID:38561191 | DOI:10.3899/jrheum.2024-0172 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - April 1, 2024 Category: Rheumatology Authors: Gabriel Nicolas Contreras Martin Source Type: research
Hospitalization and Mortality due to Infection among United States Children and Adolescents with Systemic Lupus Erythematosus
CONCLUSION: Hospitalizations with codes for for infection comprised a small proportion of cSLE admissions but accounted for the majority of mortality. The proportion of hospitalizations for infection increased over time. Lupus nephritis and ESRD were risk factors for poor outcomes.PMID:38561187 | DOI:10.3899/jrheum.2023-1219 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - April 1, 2024 Category: Rheumatology Authors: Jordan E Roberts Anna Faino Mersine A Bryan Jonathan D Cogen Esi M Morgan Source Type: research
Lupus Nephritis Treatment Strategies
J Rheumatol. 2024 Apr 1:jrheum.2024-0172. doi: 10.3899/jrheum.2024-0172. Online ahead of print.ABSTRACTLupus nephritis (LN) is present in approximately 25% to 50% of patients at the time of systemic lupus erythematosus diagnosis and eventually develops in up to 60% of adults and 80% of children.1 Over the past 5 decades, major advances in immunosuppressive medications for patients with severe LN (classes III, IV, and V alone or in combination) have resulted in significant improvements in patient survival.2.PMID:38561191 | DOI:10.3899/jrheum.2024-0172 (Source: J Rheumatol)
Source: J Rheumatol - April 1, 2024 Category: Rheumatology Authors: Gabriel Nicolas Contreras Martin Source Type: research
Hospitalization and Mortality due to Infection among United States Children and Adolescents with Systemic Lupus Erythematosus
CONCLUSION: Hospitalizations with codes for for infection comprised a small proportion of cSLE admissions but accounted for the majority of mortality. The proportion of hospitalizations for infection increased over time. Lupus nephritis and ESRD were risk factors for poor outcomes.PMID:38561187 | DOI:10.3899/jrheum.2023-1219 (Source: J Rheumatol)
Source: J Rheumatol - April 1, 2024 Category: Rheumatology Authors: Jordan E Roberts Anna Faino Mersine A Bryan Jonathan D Cogen Esi M Morgan Source Type: research
Lupus Nephritis Treatment Strategies
J Rheumatol. 2024 Apr 1:jrheum.2024-0172. doi: 10.3899/jrheum.2024-0172. Online ahead of print.ABSTRACTLupus nephritis (LN) is present in approximately 25% to 50% of patients at the time of systemic lupus erythematosus diagnosis and eventually develops in up to 60% of adults and 80% of children.1 Over the past 5 decades, major advances in immunosuppressive medications for patients with severe LN (classes III, IV, and V alone or in combination) have resulted in significant improvements in patient survival.2.PMID:38561191 | DOI:10.3899/jrheum.2024-0172 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - April 1, 2024 Category: Rheumatology Authors: Gabriel Nicolas Contreras Martin Source Type: research
Hospitalization and Mortality due to Infection among United States Children and Adolescents with Systemic Lupus Erythematosus
CONCLUSION: Hospitalizations with codes for for infection comprised a small proportion of cSLE admissions but accounted for the majority of mortality. The proportion of hospitalizations for infection increased over time. Lupus nephritis and ESRD were risk factors for poor outcomes.PMID:38561187 | DOI:10.3899/jrheum.2023-1219 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - April 1, 2024 Category: Rheumatology Authors: Jordan E Roberts Anna Faino Mersine A Bryan Jonathan D Cogen Esi M Morgan Source Type: research
